Obesity preventing or pharmaceutical composition comprising oriental medicine mixture, and injection comprising same
A herbal medicine-based pharmaceutical composition with L-Arginine, L-Carnitine, and calcium pantothenate, optimized for intravenous use, addresses the limitations of conventional obesity treatments by reducing side effects and embolism risks, offering effective obesity prevention and treatment with enhanced absorption and anti-inflammatory benefits.
Patent Information
- Application Number
- PCT/KR2024/095440
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-02-26
- Publication Date
- 2024-11-28
AI Technical Summary
Conventional obesity treatment drugs often come with severe side effects and limited effectiveness, and intravenous injections can cause embolism due to air bubbles, necessitating a safer and more effective pharmaceutical composition for obesity prevention and treatment.
A pharmaceutical composition comprising a mixture of herbal medicines, including Schisandra chinensis, Tosaja, L-Arginine, L-Carnitine, and calcium pantothenate, with a specific viscosity range and a bubble remover, designed for intravenous injection to minimize side effects and enhance absorption.
The composition effectively prevents and treats obesity with reduced side effects, improved absorption, and eliminates the risk of embolism by removing air bubbles, while providing anti-inflammatory and antioxidant benefits.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Obesity prevention or pharmaceutical composition containing a mixture of herbal medicines and an injection containing the same
[0001] The present invention relates to a pharmaceutical composition and injection for preventing obesity or containing a mixture of herbal medicines.
[0002] Recently, as the mortality rate due to adult diseases increases, interest in obesity is being focused, and accordingly, various health supplements with anti-obesity effects are being released one after another not only in Korea but also in the global pharmaceutical industry. In addition, due to economic growth, the state of consumption is improving, but in contrast, lack of exercise is becoming more serious, so the number of obese people is rapidly increasing, and the resulting increase in adult diseases is emerging as a social problem. In addition, as the eating habits of Koreans become westernized, chronic lifestyle diseases such as adult diseases are expected to increase in the future, and as we enter an aging society, the demand for silver foods targeting the elderly is also expected to increase.
[0003] Obesity occurs when the supply of energy far exceeds the demand, resulting in metabolic imbalance and excessive energy accumulation. Clinically, it contributes to or worsens the development of various diseases. Diseases related to obesity include hypertension, atherosclerosis, diabetes, fatty liver disease, and gallstones. In particular, endometrial cancer, gallbladder cancer, cervical cancer, ovarian cancer, and breast cancer are common in women, and the increase in incidence and mortality rate of endometrial cancer due to obesity is reported to be the most significant compared to other cancers. Furthermore, the mortality rate is reported to be 1.3 times higher in obese people than in people of normal weight.
[0004] Strategies for treating obesity and related disorders include dietary restrictions, increased physical activity, pharmacological approaches, and even surgery. These strategies are chosen based, at least in part, on the degree of weight loss the individual is attempting to achieve, as well as the severity of the individual's obesity. For example, treatments such as a low-calorie, low-fat diet and / or regular exercise are often appropriate for individuals with only mild overweight. However, the difficulty of maintaining long-term weight loss through diet and behavioral modification has led to increased interest in other treatment options, particularly pharmacological therapies.
[0005] Traditional pharmacological interventions typically result in weight loss of 5 to 15 kilograms; weight gain often resumes when medication is discontinued. Surgical treatment is quite successful and is reserved for patients with extreme obesity and / or serious medical comorbidities.
[0006] The above treatment may be enhanced by the controlled use of over-the-counter appetite suppressants, such as caffeine, ephedrine, and phenylpropanolamine (Acutrim, Dexatrim). Furthermore, prescription medications including amphetamines, diethylpropion (Tenuate, mazindol (Mazanor, Sanorex), phentermine (Fastin, Ionamin), phenmetrazine (Preludin), phendimetrazine (Bontrol, Plegine, Adipost, Dital, Dyrexan, Melfiat, Prelu-2, Rexigen Forte), benzphetamine (Didrex), and fluoxetine (Prozac) are often used in the treatment of severely overweight and / or obese subjects or patients.
[0007] While society has seen tremendous progress in the pharmaceutical field, there are, of course, drawbacks to the administration of any given drug. Often, the drawbacks, or "side effects," are severe enough to preclude the use of therapeutically effective doses of a particular agent. Furthermore, many agents within the same therapeutic class exhibit similar side effect profiles, meaning patients must undergo treatment or experience varying degrees of adverse effects associated with their chosen medication.
[0008] Topiramate (2,3,4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate) is a broad-spectrum neuroleptic approved by the FDA and regulatory agencies in many other countries for the treatment of certain seizure disorders and the prevention of migraine (E. Faught et al. (1996) Neurology 46:1684-90; Karim et al. (1995) Epilepsia 36 (S4):33; SK Sachdeo et al. (1995) Epilepsia 36 (S4):33; TA Glauser (1999) Epilepsia 40 (S5):S71-80; RC Sachdeo (1998) Clin. Pharmacokinet. 34:335-346). Additionally, there is evidence that topiramate is effective in treating diabetes (U.S. Patent Nos. 7,109,174 and 6,362,220), neurological disorders (U.S. Patent No. 6,908,902), depression (U.S. Patent No. 6,627,653), psychosis (U.S. Patent No. 6,620,819), headache (U.S. Patent No. 6,319,903), and hypertension (U.S. Patent No. 6,201,010). However, adverse effects associated with topiramate use in humans, such as cognitive impairment and difficulty with word finding, may discourage many obese patients from taking the drug.
[0009] Phentermine was approved by the FDA as an appetite suppressant in 1959, and phentermine hydrochloride has been used as a weight loss agent since the 1970s under brand names such as Adipex-P®, Fastin®, and Zantril®. The FDA warned against combining phentermine with a second active agent following reports of heart and lung problems associated with the "Fen-Phen" product (wherein phentermine was combined with fenfluramine and later with the related drug, dexfenfluramine), but it has been found that combining phentermine with an active agent that reduces the side effects of phentermine and allows for much lower doses of phentermine than "Fen-Phen" (containing 30 mg or 37.5 mg of phentermine hydrochloride) provides a safe and effective weight loss treatment.
[0010] Recently, Qsymia, a lower-dose combination product of topiramate and phentermine, has been developed. TM It is sold domestically and internationally under the trademark of .
[0011] However, topiramate and phentermine contained in Qsymia products are also synthetic substances and are known to have side effects such as paresthesia, alopecia, parosmia, amenorrhea, and aphasia ([Korean J Obes 2015 March;24(1):17-27, Innov Clin Neurosci. 2011 Aug;8(8):14-16.]).
[0012] Accordingly, the inventors of the present invention have discovered a composition that can eliminate or reduce the side effects of, and replace, known conventional obesity prevention and treatment compositions, and thus provide a pharmaceutical composition for obesity treatment and prevention that contains, as an active ingredient, a natural substance capable of minimizing side effects.
[0013] Research and development are currently being conducted to secure sufficient effects in improving obesity through body fat reduction and blood sugar reduction using herbal medicine mixtures, and pharmaceutical compositions for obesity prevention or treatment are being directly injected to achieve even better effects.
[0014] At this time, in order to see a more certain effect, the pharmaceutical composition for preventing or treating obesity mentioned above is administered through intravenous injection with good absorbability, but in the case of intravenous injection, if air bubbles are included, embolism is also a problem.
[0015] Therefore, research is needed on an injectable pharmaceutical composition that can ensure effectiveness when administered as an injection for the prevention or treatment of obesity and minimize side effects.
[0016] One object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity, comprising an active ingredient; a branched-chain amino acid (BCAA) comprising at least one selected from the group consisting of leucine, isoleucine, and valine; and a foam remover, wherein the active ingredient comprises a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate, the viscosity of the active ingredient is 100 cPs or more and 1000 cPs or less, and the foam remover is 0.1 part by weight or more and 0.5 part by weight or less based on 100 parts by weight of the composition.
[0017] Another object of the present invention is to provide an injection for preventing or treating obesity comprising the above composition.
[0018] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0019] According to one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity, comprising: an active ingredient; a branched-chain amino acid (BCAA) comprising at least one selected from the group consisting of leucine, isoleucine, and valine; and a defoaming agent, wherein the active ingredient comprises a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate, the viscosity of the active ingredient is 100 cPs or more and 1000 cPs or less, and the defoaming agent is 0.1 part by weight or more and 0.5 part by weight or less based on 100 parts by weight of the composition.
[0020] In one embodiment of the present invention, a pharmaceutical composition for preventing or treating obesity is provided, wherein the defoaming agent comprises a non-polar oil or a polar oil.
[0021] In one embodiment of the present invention, a pharmaceutical composition for preventing or treating obesity is provided, wherein the non-polar oil includes at least one selected from mineral oil and silicone oil, and the polar oil includes at least one selected from the group consisting of fatty alcohols, fatty acids, and alkyl amines.
[0022] In one embodiment of the present invention, a pharmaceutical composition for preventing or treating obesity is provided, wherein the active ingredient comprises a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate in a weight ratio of 1:0.01 to 0.1:0.1 to 0.5:0.1 to 0.4.
[0023] In the present invention, a pharmaceutical composition for preventing or treating obesity is provided, which further comprises at least one selected from the group consisting of catechin, cathinone, tryptamine, P-octopamine, P-tyramine, synephrine, and ephedrine.
[0024] In the present invention, a pharmaceutical composition for preventing or treating obesity is provided, wherein the effective ingredient is contained in an amount of 20 parts by weight or more and 40 parts by weight or less, based on 100 parts by weight of the pharmaceutical composition for preventing or treating obesity.
[0025] In the present invention, a pharmaceutical composition for preventing or treating obesity is provided, wherein the herbal medicine mixture is made by grinding into a fine powder at least one selected from the group consisting of Rehmannia glutinosa, Achyranthes root, Angelica gigas, Phellodendron amurense, Astragalus membranaceus, Astragalus membranaceus, Schisandra chinensis, White ginseng, White atractylodes, Sanyak root, Duzhong root, Goji berry, and Tosa jasmine, after processing and drying.
[0026] In the present invention, the herbal medicine mixture provides a pharmaceutical composition for preventing or treating obesity, which is prepared by grinding Schisandra chinensis and Tosa berry into a fine powder after being processed and dried.
[0027] Finally, an injection comprising a pharmaceutical composition for preventing or treating obesity according to the present invention is provided.
[0028] The pharmaceutical composition for preventing or treating obesity provided in the present invention contains a mixture of herbal medicines, L-Arginine, L-Carnitine, and pantothenic acid calcium as active ingredients, and exhibits an effect of preventing and treating obesity.
[0029] In particular, the pharmaceutical composition of the present invention has excellent efficacy in preventing and treating obesity while minimizing side effects by including a mixture of herbal medicines, L-arginine, L-carnitine, etc., which are natural substances that can replace the side effects of conventional synthetic drugs, as active ingredients.
[0030] Among these, the pharmaceutical composition of the present invention is characterized firstly by including the above-described active ingredient in a premixed form. That is, premixing the active ingredient does not simply mean mixing the composition included in the active ingredient, but rather means adjusting the viscosity within the above-described range through premixing.
[0031] When the viscosity is adjusted by premixing the active ingredients as described above, problems such as bacterial infection can be resolved, and thus, the obesity prevention effect can be more stably secured.
[0032] In addition, the pharmaceutical composition of the present invention is characterized by containing a certain amount of a specific anti-foaming agent. The pharmaceutical composition of the present invention is used as an injection rather than oral administration, and is particularly used for intravenous injection. Intravenous injection is characterized by a better absorption rate compared to oral or other intramuscular injections because the active ingredient is administered directly through the blood vessels, resulting in immediate effects. However, since the injection is administered intravenously, if air bubbles are included, serious side effects such as embolism may occur.
[0033] In the pharmaceutical composition according to the present application, the aforementioned foam remover is included in the content, so that air bubbles can be removed when the injection is administered, thereby eliminating the problem of embolism, and also ensuring the effect of preventing obesity.
[0034] In addition, the pharmaceutical composition of the present invention has anti-obesity, anti-inflammatory, antioxidant and detoxifying effects, i.e., detoxification effects.
[0035] However, it should be understood that the above effects are not limited to the above effects, and include all effects that can be inferred from the composition of the invention described in the detailed description or claims.
[0036] Hereinafter, the present invention will be described in detail with examples to aid understanding. However, the following examples are merely illustrative of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of ordinary skill in the art. The present invention is not limited to the examples presented herein and may be embodied in other forms.
[0037] According to one embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity, comprising: an active ingredient; a branched-chain amino acid (BCAA) comprising at least one selected from the group consisting of leucine, isoleucine, and valine; and a defoaming agent, wherein the active ingredient comprises a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate, the viscosity of the active ingredient is 100 cPs or more and 1000 cPs or less, and the defoaming agent is 0.1 part by weight or more and 0.5 part by weight or less based on 100 parts by weight of the composition.
[0038] In one embodiment of the present application, the herbal medicine mixture can facilitate the body's basal metabolism and improve the absorption rate and function of ingested substances. By performing this function, the body's basal metabolism is facilitated, thereby contributing to the prevention of obesity.
[0039] In this application, the traditional Chinese medicine mixture may be one or more selected from the group consisting of Rehmannia glutinosa, Atractylodes lancea, Angelica sinensis, Phellodendron amurense, Coptis chinensis, Astragalus membranaceus, Schisandra chinensis, Panax ginseng, Glehnia littoralis, Dioscorea opposita, Pheretima aspergillum, Lycium barbarum, and Cuscuta chinensis, which are processed, dried, and then pulverized into fine powder.
[0040] More preferably, the traditional Chinese medicine mixture may be Schisandra chinensis and Cuscuta chinensis which are processed, dried, and then pulverized into fine powder.
[0041] In this application, Schisandra chinensis (Turcz.) Baill. belongs to the genus Schisandra and is one of the traditional medicinal plants with various therapeutic properties. Previous studies have confirmed that extracts and components of Schisandrae Fructus have various beneficial pharmacological effects, including anti-inflammatory, antioxidant, neuroprotective, liver-protective, immunomodulatory, and antitumor effects. In addition, Schisandra chinensis has the effect of facilitating human basal metabolism.
[0042] In this application, "Cuscutae Semen" is the seed of Cuscuta chinensis Lam., an annual parasitic vine belonging to the family Convolvulaceae. It tastes sweet and bitter and has a neutral nature. It contains resinous glycosides, amylase, and about 40 mg% of provitamin A and sugar components. It is mainly known as a medicinal herb that protects the liver and kidneys, brightens the eyes, helps yang qi, and strengthens kidney function. It plays a role in supplementing kidney function rather than preventing obesity.
[0043] In this application, based on 100 parts by weight of the traditional Chinese medicine mixture, Schisandra chinensis may be included in an amount of 80 parts by weight or more and 90 parts by weight or less, and Cuscuta chinensis may be included in an amount of 10 parts by weight or more and 20 parts by weight or less.
[0044] In another embodiment, based on 100 parts by weight of the herbal medicine mixture, the amount of Schisandra chinensis may be 80 parts by weight or more and 85 parts by weight or less and the amount of Tosaja chinensis may be 15 parts by weight or more and 20 parts by weight or less. Specifically, the amount of Schisandra chinensis may be 85 parts by weight and the amount of Tosaja chinensis may be 15 parts by weight.
[0045] If included in the above range, the effect of preventing obesity can be maximized, but at the same time, no matter how natural the extract is, it can cause strain on the kidneys and liver, so this can be solved by including the toxin in the above content to prevent this.
[0046] The above L-arginine is an amino acid that constitutes proteins and belongs to the protein protamine found in fish sperm. As a semi-essential amino acid required for the growth of children and animals, it has been reported that the intake of L-arginine promotes the secretion of glucagon, which directly accelerates the breakdown of adipose tissue in the human body (Kalkhoff RK, et al., N Engl J Med 289: 465-467).
[0047] The above L-carnitine has the chemical name β-hydroxy-γ-N-trimethylaminobutyrate and is an amino acid analogue structurally similar to choline. However, strictly speaking, L-carnitine is not a true vitamin because some of the body's requirements can be met through biosynthesis. Rather, it can be said to be a nutrient in the form of a vitamin, like choline, taurine, and inositol.
[0048] L-carnitine's most important biological function is as an essential cofactor for fatty acid metabolism, acting as a transport molecule that facilitates the transport of fatty acids into mitochondria, converting fat into cellular energy. This function improves intracellular fatty acid and sugar metabolism.
[0049] In particular, long-chain fatty acids are activated in the outer mitochondrial membrane and oxidized in the mitochondrial matrix. These long-chain fatty acids cannot pass through the inner mitochondrial membrane without a special transport mechanism, and L-carnitine serves as the transport mechanism. In this way, long-chain fatty acids activated in the outer mitochondrial membrane temporarily bind to the hydroxyl group of L-carnitine to form long-chain fatty acids (acyl-carnitines), which are then transported into the mitochondria and metabolized.
[0050] Additionally, L-carnitine has been proven to reduce lipid accumulation in the blood and tissues in various body conditions for weight loss, and it provides energy that is essential for muscles to work, thereby improving cardiac function, increasing oxygen intake, maintaining physical strength, and reducing fat.
[0051] The above L-carnitine may be L-carnitine tartrate, which has improved preservation properties by combining tartaric acid salt.
[0052] The pharmaceutical composition for preventing or treating obesity of the present invention comprises an active ingredient, and the active ingredient may include a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate.
[0053] In one embodiment of the present application, a pharmaceutical composition for preventing or treating obesity is provided, wherein the active ingredient comprises a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate in a weight ratio of 1:0.01 to 0.1:0.1 to 0.5:0.1 to 0.4.
[0054] Specifically, the active ingredient may be included in a weight ratio of a mixture of herbal medicines, L-Arginine, L-Carnitine, and calcium pantothenate of 1:0.01 to 0.1:0.1 to 0.5:0.1 to 0.4, preferably 1:0.015 to 0.05:0.25 to 0.3:0.2 to 0.3, for example, 1:0.02:0.25:0.25.
[0055] The above herbal medicine mixture and the L-arginine may be included in a weight ratio of 1:0.01 to 0.1, and when the content of the L-arginine is less than 0.01 times the content of the herbal medicine mixture, the effect of inhibiting fat cell differentiation is reduced, and when it exceeds 0.1 times, the palatability is rapidly reduced due to a peculiar taste and smell, and problems such as stomachache, vomiting, diarrhea, and nausea may occur.
[0056] The above herbal medicine mixture and the L-carnitine may be included in a weight ratio of 1:0.1 to 0.5, and when the content of the L-carnitine is less than 0.1 times the content of the herbal medicine mixture, there is almost no effect of inhibiting fat cell differentiation, and when it exceeds 0.5 times, palatability is rapidly reduced due to a peculiar taste and smell, and problems such as stomachache, vomiting, diarrhea, and nausea may occur.
[0057] In one embodiment of the present application, the viscosity of the effective ingredient may be 100 cPs or more and 1000 cPs or less, preferably 150 cPs or more and 800 cPs or less, and more preferably 200 cPs or more and 500 cPs or less.
[0058] Among these, the pharmaceutical composition of the present invention is characterized firstly by including the above-described active ingredient in a premixed form. That is, premixing the active ingredient does not simply mean mixing the composition included in the active ingredient, but rather means adjusting the viscosity within the above-described range through premixing.
[0059] When the viscosity is adjusted by premixing the active ingredients as described above, problems such as bacterial infection can be resolved, and thus, the obesity prevention effect can be more stably secured.
[0060] In one embodiment of the present application, a Garcinia cambogia extract obtained by extracting Garcinia cambogia with an extraction solvent may be further included.
[0061] The term "compound" as used in the present invention means a product obtained by performing fractionation to separate a specific component or a specific group of components from a mixture containing various components.
[0062] The separation method for obtaining the compound in the present invention is not particularly limited and may be performed according to a method commonly used in the relevant technical field. A non-limiting example of the separation method may include a method of treating a natural substance extract with a predetermined solvent to obtain a compound from the extract.
[0063] In the present invention, the term "extracted material" or "extract" includes the extract itself and all formulations that can be formed using the extract, such as an extract obtained by extraction treatment, a diluted or concentrated extract, a dried product obtained by drying the extract, a conditioned or purified product of the extract, or a mixture thereof.
[0064] The term “extract” in this specification follows the dictionary definition and may refer to a liquid substance extracted from a specific substance or state.
[0065] The extract in this specification follows the dictionary definition and is obtained by concentrating a specific component in an extract liquid, separating a specific active component with a suitable solvent, completely or mostly evaporating the solvent, and adjusting the remaining lump or powder according to the standard. In this specification, the extract may be used to mean all three forms, namely, semi-fluid or syrup-like, pill-like or solid, and dried powder.
[0066] In the present invention, drying of the extract can be performed using known methods, as long as the useful components of the extracted natural material are not destroyed. For example, drying can be performed naturally in a shaded area. Furthermore, crushing or pulverizing can be performed to a degree that allows sufficient extraction of the plant's useful components during the subsequent extraction process. The drying and crushing or pulverizing processes can be performed in reverse order or repeated as needed.
[0067] In the extraction of the present invention, the extraction method is not particularly limited, and extraction can be performed according to a method commonly used in the relevant technical field. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, and these may be performed alone or in combination of two or more methods.
[0068] In particular, the type of extraction solvent used to extract natural substances in the present invention is not particularly limited, and any solvent known in the art can be used.
[0069] The above Garcinia cambogia is known to be effective in suppressing obesity, etc., and it is known that the result obtained by extracting the peel of the Garcinia cambogia fruit, a tropical fruit tree of the Guttiferae family, is used for the purpose of preventing or treating obesity.
[0070] The above Garcinia Cambogia extract contains hydroxycitric acid (HCA), an inhibitor of enzymes involved in the synthesis of fatty acids and cholesterol, thereby inhibiting fat synthesis, suppressing appetite, and promoting fat breakdown. HCA is a compound very similar to citric acid but with a hydroxyl group attached, and inhibits the process of citrate being converted into acetyl-coenzyme A (acetyl-Co-A) in the body, thereby suppressing fatty acid synthesis, promoting oxidation, and increasing energy production by converting it to glycogen synthesis. In addition, HCA is known to have various physiological activities such as suppressing appetite and promoting fat breakdown.
[0071] In other words, Garcinia cambogia extract blocks the pathway by which excess carbohydrates are synthesized in the spleen, acting as a factor that inhibits fat synthesis, thereby prolonging energy production within the body and increasing total energy production. In particular, Garcinia cambogia extract reduces acetyl-Co-A in the body, ultimately increasing the rate of liver and glycogen synthesis.
[0072] Accordingly, when excessive glycogen is accumulated, the hypothalamus of the brain recognizes that the body has sufficiently stored energy required, thereby reducing further energy intake. In other words, when consuming the pharmaceutical composition, health functional food composition, or health functional food additive composition for preventing or treating obesity according to the present invention, appetite is naturally suppressed, resulting in weight loss.
[0073] The above Garcinia cambogia extract is a powder form obtained by freeze-drying the peel of the Garcinia cambogia fruit, grinding it to 100 mesh or smaller, extracting it at a temperature of 80°C or higher with 70% extraction solvent, and then concentrating and freeze-drying it.
[0074] In the present invention, a Garcinia cambogia extract obtained by extracting Garcinia cambogia with an extraction solvent is used.
[0075] In the present invention, the extraction solvent is selected from the group consisting of water, C1-C4 alcohol, n-hexane, ether, glycerol, propylene glycol, butylene glycol, ethyl acetate, methyl acetate, dichloromethane, chloroform, ethyl acetate, benzene, and a mixed solvent thereof, and a pharmaceutical composition for preventing or treating obesity is provided.
[0076] Among them, the extraction solvent for making the Garcinia cambogia according to the present application into an extract comprises a modified alkylene glycol; and a solvent having a boiling point of 90°C or lower, and the extraction solvent comprises 80 parts by weight or more and 95 parts by weight or less of the modified alkylene glycol; and 5 parts by weight or more and 20 parts by weight or less of the solvent having a boiling point of 90°C or lower. A pharmaceutical composition for preventing or treating obesity is provided.
[0077] Generally, the term "glycol" refers to a compound having two hydroxyl groups (-OH), and an alkylene glycol refers to a substance having two hydroxyl group (-OH) functional groups in a straight-chain or branched alkyl group. Among these, in the case of a modified alkylene glycol as in the present application, it may refer to a substance in which at least one of the hydroxyl groups is reacted to substitute another compound.
[0078] In one embodiment of the present application, the alkylene group may include methylene, ethylene, propylene, butylene, etc., and the number of appropriate alkyl groups may include an alkylene group having 1 to 30 carbon atoms, more preferably an alkylene group having 1 to 20 carbon atoms, and most preferably an alkylene group having 1 to 5 carbon atoms.
[0079] In one embodiment of the present application, the modified alkylene glycol may include propylene glycol monomethyl ether.
[0080] In one embodiment of the present application, the solvent having a boiling point of 90°C or lower may be used without limitation among generally known solvents as long as the boiling point range satisfies the above range.
[0081] More preferably, the solvent having a boiling point of 90°C or lower may include at least one selected from the group consisting of acetone and ethyl acetate.
[0082] In the case of the organic solvent according to the present application, it may include a modified alkylene glycol; and a solvent having a boiling point of 90°C or lower, and may include 80 parts by weight or more and 95 parts by weight or less of the modified alkylene glycol; and 5 parts by weight or more and 20 parts by weight or less of the solvent having a boiling point of 90°C or lower.
[0083] In the case of the organic solvent according to the present application, it includes a modified alkylene glycol; and a solvent having a boiling point of 90°C or lower, and may contain 80 parts by weight or more and 95 parts by weight or less of the modified alkylene glycol, preferably 85 parts by weight or more and 95 parts by weight or less, and more preferably 90 parts by weight or more and 95 parts by weight or less.
[0084] In the case of the organic solvent according to the present application, it includes a modified alkylene glycol; and a solvent having a boiling point of 90°C or lower, and may be included in an amount of 5 to 20 parts by weight, preferably 5 to 15 parts by weight, and more preferably 5 to 10 parts by weight, of the solvent having a boiling point of 90°C or lower.
[0085] In one embodiment of the present application, a pharmaceutical composition for preventing or treating obesity is provided, wherein the composition includes a defoaming agent, and the defoaming agent is present in an amount of 0.1 part by weight or more and 0.5 part by weight or less based on 100 parts by weight of the composition.
[0086] In another embodiment, the composition includes a defoaming agent, and the defoaming agent may be included in an amount of 0.1 part by weight or more and 0.5 part by weight or less, preferably 0.1 part by weight or more and 0.3 part by weight or less, and more preferably 0.2 part by weight based on 100 parts by weight of the composition.
[0087] In certain embodiments, the defoaming agent can be selected from nonpolar oils such as mineral oil, silicone-based oils, polar oils such as fatty alcohols, fatty acids, alkylamines, hydrophobic solids such as treated silica, aluminum oxide, polypropylene, surfactants such as alkyl sulfates, alkyl ethoxylate sulfates, alkyl aryl sulfonates, phosphate esters, quaternary ammonium compounds, fatty amine salts, fatty acid amides, alkyl phenol ethoxylates, ethoxylate-propoxylate polymers, acrylate esters, fatty alcohol ethoxylates, and combinations thereof.
[0088] In one embodiment of the present application, a pharmaceutical composition for preventing or treating obesity is provided, wherein the defoaming agent comprises a non-polar oil or a polar oil, wherein the non-polar oil comprises at least one selected from a mineral oil and a silicone oil, and the polar oil comprises at least one selected from a group consisting of a fatty alcohol, a fatty acid, and an alkyl amine.
[0089] The pharmaceutical composition of the present invention is administered as an injection rather than orally, and is particularly used for intravenous injection. In the case of intravenous injection, the active ingredient is administered directly through the blood vessel, and thus has a better absorption rate than oral or other intramuscular injections, so the effect appears immediately. However, since the injection is administered into the vein, if air bubbles are included in it, serious side effects such as embolism may occur. The pharmaceutical composition according to the present application includes the aforementioned anti-foaming agent in the content, so that air bubbles can be removed during injection, thereby eliminating the problem of embolism, and also has the characteristic of ensuring the effect of preventing obesity.
[0090] The composition of the present invention may further include one or more of Catechin, Cathinone, Tryptamine, P-Octopamine, P-Tyramine, Synephrine, and Ephedrine, which are norepinephrine releasing substances, and the norepinephrine acts as a neurotransmitter in the neural synapses between the brain and muscles, and acts as a hormone that regulates fuel metabolism in the liver and muscles.
[0091] In the present invention, the pharmaceutical composition for preventing or treating obesity may be a compound that stimulates the hypothalamus to increase norepinephrine secretion, and specifically, may be a compound that increases appetite suppression and energy consumption by increasing the concentration of norepinephrine in the synapse and activating hypothalamic POMC neurons.
[0092] The above catechin can be extracted from the tea tree (Camellia sienesis), and can act as a substance for preventing and treating obesity by inhibiting the COMT (catechol O-methyltransferase) enzyme, increasing norepinephrine in the synaptic gap, and thus being effective in energy activity ([Korean J Clin Pharm 2018;28(4):342-346, ARYA Atheroscler. 2014 Jan; 10(1): 55-58.]).
[0093] The above cathinone can be extracted from Catha edulis (Khat), and like amphetamine, it releases catecholamines, such as dopamine, norepinephrine, and epinephrine, through TAAR1 activation, and acts on alpha and beta adrenergic receptors to exhibit an appetite suppressing effect. The above cathinone has a greater CNS activating effect than amphetamine ([Cathinone (Khat) and Methcathinone (CAT) in Urine Specimens: A Gas Chromatographic-Mass Spectrometric Detection Procedure], [MECHANISM OF ACTION OF CATHINONE: THE ACTIVE INGREDIENT OF KHAT (CATHA EDULIS)]).
[0094] The above tryptamine can be extracted from Vachellia aroma, and can act as a substance for preventing and treating obesity with a complex mechanism that includes the effect of reducing fasting blood sugar in the liver by increasing insulin in the pancreas through the TAAR1 receptor, delaying the time of food emptying from the stomach, increasing GLP-1 & PYY, and reducing glucose excretion from the body ([Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges], [Pharmacology & Therapeutics, Volume 180, December 2017, Pages 161-180]).
[0095] The above P-octopamine can be extracted from bitter orange (Citrus aurantium), and can act as a substance for preventing and treating obesity by increasing the release of serotonin through the TAAR1 receptor, thereby increasing satiety and reducing food intake. In addition, P-octopamine acts on the Beta 3 Adrenergic receptor of fat cells to activate the Beta 3 Adrenergic receptor, induces the conversion of white fat into brown fat through binding activation of norepinephrine in fat cells and activation of UCP-1 protein, and increases energy consumption through thermogenesis by brown fat, so it can act as a substance for preventing and treating obesity ([Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges], [Pharmacology & Therapeutics, Volume 180, December 2017, Pages 161-180]).
[0096] The above P-tyramine can be extracted from Bitter Orange (Citrus aurantium) or Musa sapientum L, and can act as a substance for the prevention and treatment of obesity with a complex mechanism that includes the effect of reducing fasting blood sugar in the liver by increasing insulin in the pancreas through the TAAR1 receptor, delaying the time of food emptying from the stomach and increasing GLP-1 & PYY, thereby reducing glucose excretion from the body ([Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges], [Pharmacology & Therapeutics, Volume 180, December 2017, Pages 161-180]).
[0097] The above synephrine can be extracted from bitter orange (Citrus aurantium), and can act as a substance for preventing and treating obesity by releasing catecholamines through TAAR1 activation, activating lipolysis by binding to the β 3 adrenergic receptor, and increasing norepinephrine to show efficacy in energy activity ([Phytother Res. 2017 Oct; 31(10): 1463-1474.]).
[0098] The above ephedrine can be extracted from Ephedra sinica, and acts mainly on α and β adrenergic receptors, stimulates the sympathetic nerves, increases norepinephrine in the synaptic gap, and is effective in energy activity, so it can act as a substance for preventing and treating obesity ([Anesth Prog. 2012 Winter; 59(4): 159-169.]).
[0099] It is preferable that the pharmaceutical composition of the present invention contains catechin as a norepinephrine releasing substance.
[0100] The pharmaceutical composition for preventing or treating obesity of the present invention may include a mixture of herbal medicines, L-arginine, the L-carnitine, and the catechin in a weight ratio of 1:0.01 to 0.1:0.1 to 0.5:0.5 to 2.
[0101] The above herbal medicine mixture and the catechin may be included in a weight ratio of 1:0.5 to 1:2, and when the content of the catechin is less than 0.5 times the content of the herbal medicine mixture, the effect of inhibiting fat cell differentiation is reduced, and when it is more than 2 times, a problem of cytotoxicity occurs.
[0102] For example, the composition may be comprised in a weight ratio of 1:0.015 to 0.05:0.05 to 0.4:0.1 to 0.2 to maximize the effect of inhibiting adipocyte differentiation while preventing or minimizing cytotoxicity.
[0103] In the present invention, the composition may include branched-chain amino acids (BCAA) including at least one selected from the group consisting of leucine, isoleucine, and valine, calcium pantothenate, nicotinamide, crystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, and calcium carboxymethylcellulose.
[0104] The above branched-chain amino acid (BCAA) is one of the essential amino acids that has a close relationship with muscles, and the above calcium pantothenate (molecular formula C) 18 H 32 O 10N2Ca) is a white powder, odorless, slightly bitter-tasting calcium salt fortifier that acts as a coenzyme in the body and is necessary for normalizing tissue function, body growth, and maintaining health.
[0105] The above nicotinamide is a type of vitamin, and the above vitamin is added for obesity prevention and dieting, and refers to vitamins B1, B2, B6, B12, C, D3, and nicotinamide. Vitamins B, C, D, and nicotinamide act as coenzymes in the TCA cycle, which breaks down glucose to create energy. If there are no vitamins, this process cannot proceed, and nutrients are not consumed as energy, but are converted to body fat and stored in the body. In other words, if there are not enough vitamins, the food you eat cannot be used as energy, but is stored in the body, which ultimately leads to obesity.
[0106] The above-mentioned crystalline cellulose is an additive used as an anti-caking agent, stabilizer, emulsifier, and dietary fiber agent in food, the above-mentioned magnesium stearate provides mineral components by supplying magnesium, and the above-mentioned hydroxypropyl methyl cellulose (hypromellose, HPMC) and the above-mentioned carboxymethyl cellulose calcium act as viscosity modifiers.
[0107] Additionally, the composition may further include additives such as zinc oxide and silicon dioxide.
[0108] In the present invention, the term "prevention" refers to any action that suppresses or delays obesity, and the term "treatment" refers to any action that improves or beneficially changes the symptoms of a subject suspected of or diagnosed with obesity. In addition, the pharmaceutical composition may be provided as a pharmaceutical composition containing the active ingredient alone, or including one or more pharmaceutically acceptable carriers, excipients, or diluents. As used herein, "pharmaceutically acceptable" refers to a composition that is physiologically acceptable and does not typically cause an allergic reaction or similar reaction when administered to a human.
[0109] Furthermore, the pharmaceutical composition may be provided in combination with a conventionally known anti-obesity agent. That is, the pharmaceutical composition may be administered in combination with a known compound having an effect of preventing or treating obesity.
[0110] The above "administration" means introducing a given substance to an individual through an appropriate method, and "individual" means any animal, including rats, mice, livestock, etc., including humans, that has developed or may develop obesity. A specific example may be a mammal, including humans.
[0111] Furthermore, in the present invention, "obesity" refers to something caused by energy imbalance, and the causes of obesity are complexly related to hormonal changes, genetics, mental health issues, and socioeconomic factors. Specifically, it refers to something that can be caused by energy imbalance, genetic factors, neuroendocrine factors, and environmental factors.
[0112] The route of administration of the above pharmaceutical composition is not limited to these, but in the case of the present application, it is used as an injection, and in particular, it is used for intravenous injection.
[0113] For parenteral administration, the preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin, and the like. In addition, the preparations may be formulated in the form of injections, creams, lotions, topical ointments, oils, moisturizers, gels, aerosols, and nasal inhalers using methods known in the art. These formulations are described in the literature ([Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour]), a generally known prescription for all pharmaceutical chemistry.
[0114] The preferred dosage of the pharmaceutical composition above varies depending on the patient's condition and weight, the severity of the disease, the drug form, the route and duration of administration, and can be appropriately selected by those skilled in the art. However, for a desirable effect, the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. Preferably, the preferred total dosage of the composition of the present invention may be about 0.01 ㎍ to 1,000 mg per 1 kg of the patient's body weight per day, and most preferably 0.1 ㎍ to 100 mg. However, since the dosage of the composition is determined by taking into consideration various factors such as the route of administration of the pharmaceutical composition and the number of treatments as well as the patient's age, weight, health condition, sex, severity of the disease, diet, and excretion rate, a person having ordinary skill in the art will be able to determine an appropriate effective dosage according to a specific use of the composition as an agent for preventing or treating obesity. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, or method of administration as long as it exhibits the effects of the present invention. When formulating the above pharmaceutical composition, it is prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants that are commonly used.
[0115] Furthermore, the pharmaceutical composition of the present invention can be used not only as a human medicine but also as an animal medicine. Here, the term "animal" includes livestock and pets.
[0116] According to another embodiment of the present invention, an injection comprising a pharmaceutical composition for preventing or treating obesity according to the present application is provided.
[0117] When formulating the above injection, it is prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants that are commonly used.
[0118] Below, for more specific explanation, examples will be given to provide a detailed explanation.
[0119] Example
[0120] <Preparation of a mixture of herbal medicines>
[0121] The peel of the Schisandra chinensis fruit was freeze-dried, ground to a size of 100 mesh or less, and extracted with 70% extraction solvent (water) at a temperature of 80°C or higher.
[0122] Tosaja (purchased from the herb Dosonae) was freeze-dried, ground to 100 mesh or less, and extracted with 70% extraction solvent (water) at a temperature of 80℃ or higher.
[0123] The herbal medicine mixture was formed by mixing the corresponding Omija and Tosaja in a ratio of 85:15.
[0124] <Manufacturing of active ingredients>
[0125] An effective ingredient satisfying the composition, content, and viscosity of Table 1 below was manufactured. At this time, the composition was pre-mixed to adjust the viscosity as follows.
[0126] Medicinal Herb Mixture L-Arginine L-Carnitine Calcium Pantothenate Viscosity (cPs) Example 1 100g 2g 25g 25g 350 Example 2 100g 2g 25g 25g 360 Comparative Example 1 100g 2g 25g 25g 90 Comparative Example 2 100g 2g 25g 25g 1500 (No pre-mixing) Comparative Example 3 100g 2g 25g 25g 350 Comparative Example 4 100g 2g 25g 25g 350 Comparative Example 5 100g 2g 25g 25g 350
[0127] <Manufacture of a pharmaceutical composition for preventing or treating obesity> A pharmaceutical composition for preventing or treating obesity was manufactured by mixing 0.1 g of BCAA mix as an additional mixing ingredient into a composition containing the above active ingredient.
[0128] At this time, in the above Examples 1, 2, Comparative Examples 1 and 2, 0.2 parts by weight of a foaming agent composed of a non-polar oil, mineral oil: silicone oil = 1:1, was included based on 100 parts by weight of the pharmaceutical composition for preventing or treating obesity.
[0129] In the case of Comparative Example 3, 0.05 parts by weight of a defoaming agent was included, in the case of Comparative Example 4, 1 part by weight of a defoaming agent was included, and in the case of Comparative Example 5, no defoaming agent was included.
[0130] Manufacturing Example 1. INS-1 cell culture
[0131] Rat pancreatic β-cells (INS-1) purchased from Biohermes (Shanghai, China) were cultured in RPMI-1640 (Cellgro, Manassas, VA, USA) containing 11 mM D-glucose, 10% fetal bovine serum, 1% penicillin / streptomycin (Invitrogen Co., Grand Island, NY, USA), 0.05 mM 2-mercaptoethanol, 2 mM L-glutamine, 10 mM hydroxyethylpiperazineethanesulfonic acid (HEPES), and 1 mM sodium pyruvate at 37°C, 5% CO2, and 95% humidity.
[0132] Manufacturing Example 2. 3T3-L1 cell culture
[0133] 3T3-L1 preaidpocyte cells purchased from ATCC (American Type Culture Collection, USA) were subcultured in DMEM (containing 10% Bovine Serum, 100 units / ml penicillin, 100 ug / ml streptomycin) medium and used to induce adiocyte differentiation and adipogenesis.
[0134] Preadipocyte cells were used as the normal group, and preadipocyte cells were cultured to a post-confluent state after seeding as a control group. After differentiation was induced for 3 days using Zenbio DM medium according to Zenbio manual, adipocytes were maintained for 4 days using Zenbio AM medium by changing the medium once every two days.
[0135] The experimental group was treated with Hispidulin, Synephrine, and P-Octopamine (Octopamine hydrochloride) at concentrations of 0, 5, 10, 20, or 40 μM each time the DM medium and AM medium were treated under the same culture conditions as the control group.
[0136]
[0137] Experimental Example 1. Cell viability test and adipocyte differentiation inhibition effect
[0138] Using 3T3-L1 cells, which are adipogenic cells derived from mice, the effects of Hispidulin, Synephrine, and P-Octopamine (Octopamine hydrochloride) on cell viability were evaluated as follows.
[0139] In the normal group of the manufacturing example, 3T3-L1 preadipocyte cells were seeded at 1X10 per well in a 96-well plate. 4After dividing into dogs, the cells were cultured under the same conditions for 24 hours to ensure stability.
[0140] Thereafter, the compositions of Examples 1 to 2 and Comparative Examples 1 to 5 (compositions before mixing additional mixed components) at a concentration of 200 ug / ml were each treated and cultured under the same conditions for 24 hours. Thereafter, EZ-Cytox cell viability assay solution (100 μL; Daeil Lab Service Co., Ltd., Seoul) was added to the plate and cultured for 40 minutes. Next, the absorbance of the samples in the well plate was measured at a wavelength of 450 nm using a PowerWave XS microplate reader (Bio-Tek Instruments, Winooski, VT, USA) to determine the cell viability.
[0141] It was confirmed that the compositions of Examples 1 to 2 and Comparative Examples 1 to 5 did not show a significant difference in the number of 3T3-L1 cells. Therefore, it was confirmed that the compositions of Examples 1 to 2 and Comparative Examples 1 to 5 were all non-toxic to 3T3-L1 cells.
[0142] In addition, 3T3-L1 cells were treated with the compositions of Examples 1 to 2 and Comparative Examples 1 to 5 each time they were treated with DM medium and AM medium under the same culture conditions as the control group of the manufacturing example. Then, in order to confirm the effect of the compositions of Examples 1 to 2 and Comparative Examples 1 to 5 on fat accumulation, the culture medium of the cells of each group was removed and the amount of fat accumulation within the cells was compared and confirmed through the Oil red O test as shown in Table 2.
[0143] Example Cell Viability (%) Oil Red O (%) Example 196.5±2.5 3 2.1±3.2 Example 298.1±2.7 4 3.3±2.1 Comparative Example 196.1±2.7 6 6.3±2.2 Comparative Example 294.5±3.4 4 9.2±2.3 Comparative Example 395.6±1.9 4 7.6±2.1 Comparative Example 494.5±3.4 6 5.3±2.2 Comparative Example 595.6±1.9 4 4.3±2.6
[0144] Experimental Example 2. Stability Evaluation The compositions of Examples 1 to 2 and Comparative Examples 1 to 5 were stored and evaluated for factors related to bacterial infection after 20 hours, and the results are shown in Table 3 below. In addition, when the compositions were administered to rats purchased from Biohermes (Shanghai, China), whether or not they caused embolism problems is shown in Table 3 below. At this time, the injection of the injection was generally pretreated in the same manner to remove air bubbles.
[0145] Example Bacterial infection rate (%) Embolism incidence rate (%) Example 10.2±0.03 0.1±0.06 Example 20.18±0.03 0.15±0.03 Comparative example 10.2±0.03 0.2±0.06 Comparative example 214.1±0.02 0.15±0.03 Comparative example 30.2±0.03 12.6±2.1 Comparative example 40.21±0.04 0.1±0.06 Comparative example 50.22±0.02 29.3±2.6
[0146] When the injections of Examples 1 and 2 were administered intravenously, it was confirmed that the intended obesity prevention effect was achieved, along with stability (embolism, bacterial infection). In the case of Comparative Example 1, since the viscosity was below the range of the present application, no problems with bacterial infection or embolism occurred, but since the active ingredient did not have sufficient viscosity, it was confirmed that absorption into the blood vessels was not performed well when administered intravenously, and thus the amount of fat accumulation was higher than in other Examples and Comparative Examples.
[0147] In the case of Comparative Example 2, since the premixing of the active ingredient was not performed, the viscosity was formed to be high, and it was confirmed that the rate of bacterial infection increased due to the increase in the viscosity of the active ingredient itself, resulting in side effects.
[0148] In the case of Comparative Example 3, a small amount of a defoaming agent was added, and in the case of Comparative Example 5, a defoaming agent was not included. In both Comparative Examples 3 and 5, it was confirmed that the incidence of embolism increased. This corresponds to the result due to the problem of air bubbles in the composition.
[0149] In the case of Comparative Example 4, a large amount of defoaming agent was added, which may be effective in defoaming, but as can be seen in Table 2, the amount of fat accumulation was measured to be higher than in other examples. This corresponds to the result of the inclusion of the defoaming agent resulting in a lower content of other effective ingredients.
[0150] Although exemplary embodiments of the present invention have been described above, the present invention is not limited thereto, and those skilled in the art will understand that various changes and modifications are possible within the scope and spirit of the claims set forth below.
Claims
1. A pharmaceutical composition for preventing or treating obesity, comprising: an active ingredient; a branched-chain amino acid (BCAA) comprising at least one selected from the group consisting of leucine, isoleucine, and valine; and a foaming agent; The above active ingredients include a mixture of herbal medicines, L-Arginine, L-Carnitine and calcium pantothenate. The viscosity of the above active ingredient is 100 cPs or more and 1000 cPs or less, The above herbal medicine mixture is a mixture of Schisandra chinensis and Tosa chinensis in a ratio of 85:
15. The above defoaming agent comprises a non-polar oil, The above non-polar oil is a mixture of mineral oil and silicone oil in a 1:1 ratio. A pharmaceutical composition for preventing or treating obesity, wherein the above-mentioned foam remover is present in an amount of 0.1 part by weight or more and 0.5 part by weight or less based on 100 parts by weight of the composition.
2. In claim 1, A pharmaceutical composition for preventing or treating obesity, wherein the above active ingredients comprise a mixture of herbal medicines, L-arginine, L-carnitine, and calcium pantothenate in a weight ratio of 1:0.01 to 0.1:0.1 to 0.5:0.1 to 0.
4.
3. In paragraph 1, A pharmaceutical composition for preventing or treating obesity, wherein the active ingredient is contained in an amount of 20 parts by weight or more and 40 parts by weight or less, based on 100 parts by weight of the pharmaceutical composition for preventing or treating obesity.
4. An injectable for preventing or treating obesity comprising a pharmaceutical composition for preventing or treating obesity according to any one of claims 1 to 3.
Citation Information
Patent Citations
Natural functional food for Anti-obesity wellbeing diet and its producing method
KR1020110121246A
Food composition for Anti-obesity and preparation thereof
KR1020130075036A
Method for manufacturing functional pill product using male silkworm as main material
KR1020140074422A
Lubricant defoaming additives and compositions
KR1020150128912A
Pharmaceutical composition for preventing or treating obesity having garcinia cambogia extract and health functional food having the same
KR102461437B1
